Perigon Wealth Management LLC Buys Shares of 1,868 West Pharmaceutical Services, Inc. $WST

Perigon Wealth Management LLC bought a new stake in West Pharmaceutical Services, Inc. (NYSE:WST) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 1,868 shares of the medical instruments supplier’s stock, valued at approximately $671,000.

Several other hedge funds also recently modified their holdings of the company. Empowered Funds LLC grew its holdings in shares of West Pharmaceutical Services by 16.1% during the first quarter. Empowered Funds LLC now owns 1,611 shares of the medical instruments supplier’s stock worth $361,000 after buying an additional 224 shares in the last quarter. Intech Investment Management LLC lifted its stake in shares of West Pharmaceutical Services by 27.7% during the first quarter. Intech Investment Management LLC now owns 6,020 shares of the medical instruments supplier’s stock valued at $1,348,000 after buying an additional 1,307 shares during the period. Acadian Asset Management LLC boosted its position in West Pharmaceutical Services by 14.1% during the first quarter. Acadian Asset Management LLC now owns 1,271 shares of the medical instruments supplier’s stock worth $284,000 after acquiring an additional 157 shares during the last quarter. EverSource Wealth Advisors LLC boosted its position in West Pharmaceutical Services by 78.2% during the second quarter. EverSource Wealth Advisors LLC now owns 449 shares of the medical instruments supplier’s stock worth $98,000 after acquiring an additional 197 shares during the last quarter. Finally, First Trust Advisors LP grew its stake in West Pharmaceutical Services by 168.4% in the 2nd quarter. First Trust Advisors LP now owns 46,332 shares of the medical instruments supplier’s stock worth $10,137,000 after acquiring an additional 29,067 shares during the period. 93.90% of the stock is owned by institutional investors and hedge funds.

West Pharmaceutical Services Trading Up 1.7%

NYSE:WST opened at $352.32 on Thursday. The business’s 50-day moving average is $347.64 and its two-hundred day moving average is $298.51. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.82 and a quick ratio of 2.12. West Pharmaceutical Services, Inc. has a 12 month low of $223.83 and a 12 month high of $386.00. The firm has a market capitalization of $24.80 billion, a PE ratio of 45.11, a price-to-earnings-growth ratio of 2.42 and a beta of 1.15.

West Pharmaceutical Services (NYSE:WST) last issued its earnings results on Thursday, July 23rd. The medical instruments supplier reported $2.37 earnings per share for the quarter, topping the consensus estimate of $2.08 by $0.29. West Pharmaceutical Services had a return on equity of 20.11% and a net margin of 16.98%.The company had revenue of $872.30 million during the quarter, compared to the consensus estimate of $839.98 million. During the same quarter in the prior year, the business earned $1.84 earnings per share. The company’s revenue was up 13.8% compared to the same quarter last year. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. Research analysts predict that West Pharmaceutical Services, Inc. will post 8.93 earnings per share for the current fiscal year.

West Pharmaceutical Services Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, August 5th. Investors of record on Wednesday, July 29th were given a dividend of $0.22 per share. The ex-dividend date of this dividend was Wednesday, July 29th. This represents a $0.88 annualized dividend and a yield of 0.2%. West Pharmaceutical Services’s payout ratio is 11.27%.

Wall Street Analyst Weigh In

Several research analysts have weighed in on WST shares. Barclays upgraded West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $310.00 to $400.00 in a report on Tuesday, June 9th. Weiss Ratings upgraded West Pharmaceutical Services from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, August 7th. BNP Paribas Exane assumed coverage on West Pharmaceutical Services in a research report on Monday, July 13th. They set an “outperform” rating and a $447.00 target price on the stock. Citigroup raised their price target on West Pharmaceutical Services from $400.00 to $412.00 and gave the stock a “buy” rating in a research note on Monday, August 3rd. Finally, Wolfe Research began coverage on West Pharmaceutical Services in a research note on Monday, June 1st. They issued an “outperform” rating and a $375.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $368.08.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.